The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Repurposing ibrutinib for chemo-immunotherapy in a phase 1b study of ibrutinib with indoximod plus metronomic cyclophosphamide and etoposide for patients with childhood brain cancer.
 
Theodore S. Johnson
Research Funding - Janssen Scientific Affairs; Lumos Pharma
 
Rafal Pacholczyk
No Relationships to Disclose
 
Sarthak Satpathy
No Relationships to Disclose
 
Zuzana Berrong
No Relationships to Disclose
 
Julianne Creager
Employment - Lumos Pharma
Stock and Other Ownership Interests - Lumos Pharma
 
Chenbin Huang
No Relationships to Disclose
 
Eugene Paul Kennedy
Employment - CSL Limited (I); Galera Therapeutics
Leadership - Galera Therapeutics
Stock and Other Ownership Interests - CSL Behring (I); Galera Therapeutics; Lumos Pharma
 
Eric K. Ring
No Relationships to Disclose
 
Ramses F. Sadek
No Relationships to Disclose
 
Beena E. Thomas
No Relationships to Disclose
 
Manoj K. Bhasin
Consulting or Advisory Role - Sanofi
 
David H. Munn
Stock and Other Ownership Interests - Lumos Pharma
Patents, Royalties, Other Intellectual Property - patents and royalties regarding IDO-inhibitor drugs
(OPTIONAL) Uncompensated Relationships - C -inventor on patents licensed to Lumos Pharma